HBsAg Kinetics After 7 Years of Therapy with Tenofovir Disoproxil Fumarate in a Cohort of Naïve Patients Affected by Chronic Hepatitis B with Different Genotypes

Overview

Journal Infect Med (Beijing)

Date 2024 Mar 7

PMID 38450105

Authors

Lucio Boglione

Tommaso Lupia

Giacomo Stroffolini

Valentina Dodaro

Giovanni Di Perri

Affiliations

Soon will be listed here.

Abstract

The role of different genotypes in nucleos(t)ide analogs (NAs) treatment is still debated. Previous studies conducted on special populations evidenced that the E genotype had the lower virological and serological response. This descriptive study aims to recognize the hepatitis B "s" antigen (HBsAg) decline during tenofovir disoproxil fumarate (TDF) treatment in a cohort of patient affected by chronic hepatitis B (CHB). We retrospectively included all patients with CHB treated with TDF between April 2007 and March 2012 with a duration of treatment of 7 years. Kinetics of HBsAg was determined as serological response in this cohort. We include 110 subjects; virological response was observed in all subjects with genotypes A, B, and D; in 17 patients with C genotype (94.4%) and 24 with E genotype (96%). HBeAg loss was observed in 2 patients with genotype A (50%), 3 with B (100%), 0 with C (0%), 1 with D (20%), and 1 with E genotype (25%). In multivariate analysis we observed as predictive factors of HBsAg decline the baseline level of HBsAg (OR = 1.467; 95%CI: 1.221-5.113; = 0.017) and viral genotypes (OR = 11.218; 95%CI: 5.441-41.138; < 0.001). This study confirmed higher HBsAg decline after 7 years of treatment in A and B genotypes, and lower in C, E, and D genotypes. However, no evidence is enough to choose a single NAs, but in special populations, as well as in genotype E, the use of TDF should be preferred to entecavir.

References

Boglione L, De Benedetto I, Lupia T, Cusato J, Cariti G, Di Perri G . Serological and virological response in patients with hepatitis B virus genotype E treated with entecavir or tenofovir: a prospective study. Arch Virol. 2021; 166(4):1125-1131. DOI: 10.1007/s00705-021-04992-5. View

Erhardt A, Blondin D, Hauck K, Sagir A, Kohnle T, Heintges T . Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut. 2005; 54(7):1009-13. PMC: 1774609. DOI: 10.1136/gut.2004.060327. View

Yuen M, Chen D, Dusheiko G, Janssen H, Lau D, Locarnini S . Hepatitis B virus infection. Nat Rev Dis Primers. 2018; 4:18035. DOI: 10.1038/nrdp.2018.35. View

Boglione L, DAvolio A, Cariti G, Gregori G, Burdino E, Baietto L . Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D. Liver Int. 2013; 33(4):580-5. DOI: 10.1111/liv.12091. View

Kuhnhenn L, Jiang B, Kubesch A, Vermehren J, Knop V, Susser S . Impact of HBV genotype and mutations on HBV DNA and qHBsAg levels in patients with HBeAg-negative chronic HBV infection. Aliment Pharmacol Ther. 2018; 47(11):1523-1535. DOI: 10.1111/apt.14636. View

Buster E, Hansen B, Lau G, Piratvisuth T, Zeuzem S, Steyerberg E . Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology. 2009; 137(6):2002-9. DOI: 10.1053/j.gastro.2009.08.061. View

Boglione L, Cardellino C, De Nicolo A, Cariti G, Di Perri G, DAvolio A . Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E. J Med Virol. 2014; 86(11):1845-50. DOI: 10.1002/jmv.24038. View

Lin C, Kao J . Natural history of acute and chronic hepatitis B: The role of HBV genotypes and mutants. Best Pract Res Clin Gastroenterol. 2017; 31(3):249-255. DOI: 10.1016/j.bpg.2017.04.010. View

Revill P, Tu T, Netter H, Yuen L, Locarnini S, Littlejohn M . The evolution and clinical impact of hepatitis B virus genome diversity. Nat Rev Gastroenterol Hepatol. 2020; 17(10):618-634. DOI: 10.1038/s41575-020-0296-6. View

10.

Boglione L, Cusato J, Cariti G, Di Perri G, DAvolio A . The E genotype of hepatitis B: clinical and virological characteristics, and response to interferon. J Infect. 2014; 69(1):81-7. DOI: 10.1016/j.jinf.2014.02.018. View

11.

. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017; 67(2):370-398. DOI: 10.1016/j.jhep.2017.03.021. View

12.

Schaefer S . Hepatitis B virus taxonomy and hepatitis B virus genotypes. World J Gastroenterol. 2007; 13(1):14-21. PMC: 4065870. DOI: 10.3748/wjg.v13.i1.14. View

13.

Fernandes da Silva C, Keeshan A, Cooper C . Hepatitis B virus genotypes influence clinical outcomes: A review. Can Liver J. 2023; 6(3):347-352. PMC: 10652982. DOI: 10.3138/canlivj-2023-0003. View

14.

Glebe D, Goldmann N, Lauber C, Seitz S . HBV evolution and genetic variability: Impact on prevention, treatment and development of antivirals. Antiviral Res. 2020; 186:104973. DOI: 10.1016/j.antiviral.2020.104973. View